Results 91 to 100 of about 165,865 (302)
Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
, 2016 Barbara Legius,1 Sandra Van Den Broecke,1 Inge Muylle,1 Vincent Ninane1,2 1Department of Pulmonology, Centre Hospitalier Universitaire Saint Pierre, 2Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium Abstract: Non-small cell ...
Van Den Broecke S +3 more
core
Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis
Molecular Oncology, EarlyView.This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht +3 more
wiley +1 more source
Double Agent: SPDEF Gene with Both Oncogenic and Tumor-Suppressor Functions in Breast Cancer
Cancer Management and Research, 2020 Ting Ye,* Jia Feng,* Xue Wan, Dan Xie, Jinbo Liu Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan 646000, People’s Republic of China*These authors contributed equally to this workCorrespondence ...
Ye T, Feng J, Wan X, Xie D, Liu J
doaj
Ultrabright gap-enhanced Raman tags for high-speed bioimaging
Nature Communications, 2019 The speed of surface-enhanced Raman spectroscopy (SERS) imaging is generally limited due to low Raman signals. Here, the authors develop bright gap-enhanced Raman tags with external hot spots and demonstrate their use in fast near-infrared bioimaging.
Yuqing Zhang +4 more
doaj +1 more source
, 1996 Oncogenes and anti-oncogenes form two families of genes. If abnormal both may induce malignancies. They are distinguished, however, by two components. Oncogenes play a certain role in a given period of development (mainly during organogenesis).
Munier, F. L., Schorderet, D. F.
core
ONCOGENES IN THE CANCER OF THE PANCREAS
, 1995 GENETIC ALTERATIONS ARE FREQUENTLY ASSOCIATED WITH NEOPLASIA. THESE GENETIC CHANGES ALTER CELLULAR PROTO-ONCOGENES AND/OR THEIR "SUPPRESSOR" GENES AND CONTRIBUTE TO THE MANIFESTATIONS OF THE MALIGNANT PHENOTYPE.
Σακοράφας, Γεώργιος
core +1 more source
Molecular Oncology, EarlyView.Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski +12 more
wiley +1 more source
Molecular Oncology, EarlyView.Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller +10 more
wiley +1 more source
, 2019 The recent advancements in CRISPR/Cas9 engineering have resulted in the development of more targeted and potentially safer gene therapies. The challenge in the cancer setting is knowing the driver oncogenes responsible, and the translation of these ...
Jubair, L, McMillan, NAJ, Fallaha, S
core +1 more source
Molecular Oncology, EarlyView.Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source